YOU MAY FIND THESE HELPFUL
Start here.
High Performance Is Not a Health Assessment, and a…
ExploreRead & learnA Medal Is Not a Mental-Health Assessment
ExploreRead & learnIs Not an Outcome
ExploreAssessment & Treatment Planning
ExplorePlan your stayHow Admission Works
ExploreRead & learnHigh Performance Is Not a Health Assessment, and a…
ExploreHow it connects
Presentation before label
Symptoms are understood in context, including overlap and co-occurring needs.
- 01History
- 02Current safety
- 03Patterns
- 04Needs
Clinical resource
One Dose, One Year Later: The Psilocybin Results That Complicate the Breakthrough Story
Two European trials published in 2026 found different answers at different endpoints. German primary-response results and Swedish one-year follow-up show why rapid improvement is…
Read →Clinical resource
Ten Minutes Is Not a Treatment Plan: What the New DMT Trial Really Measures
A UK-led DMT trial reported a positive two-week depression result. Its brief administration, controlled phase and longer open-label follow-up are different parts of the…
Read →Clinical resource
A Faster Schedule Is Not Proof of a Better Treatment: The New TMS Evidence
Two 2026 stimulation trials asked different questions. One supported a compressed schedule against standard treatment; another found no significant advantage over sham despite personalized…
Read →Clinical resource
The Diet Study Has Two Timelines. Only One Was Randomized.
A 2026 ketogenic-diet trial strengthens the metabolic evidence while leaving psychiatric durability questions open. Its one-month randomised comparison and four-month extension should not be…
Read →Clinical resource
A Brain Scan Can Classify a Pattern. Can It Choose Your Treatment?
A six-biotype depression study offers a promising research framework. It does not, by itself, establish that buying a scan will produce a better treatment…
Read →Clinical resource
59 Candidates, Two Starting Arms: Europe’s Next Depression Breakthrough May Be a Better Trial
EU-PEARLDIVER proposes a shared European platform for testing depression treatments. Its significance is a plan for stronger comparisons—not evidence that the selected drugs have…
Read →Clinical resource
Two Specialists. One Patient: Bahrain’s Physical and Mental-Health Coordination Question
Newly published Bahrain research links reported physical symptoms with academic disruption, while local treatment findings remain preliminary. What should coordinated private care actually demonstrate?
Read →Clinical resource
Oman Is Adding Addiction-Treatment Capacity. What Happens After Discharge?
Oman's new rehabilitation capacity raises a question relevant to families choosing care locally or abroad: who measures recovery after the residential stay?
Read →Clinical resource
One Gulf, Six Different Measures: Why More Mental-Health Care Is Not Yet a Comparable Recovery Story
A six-country examination of Gulf mental-health evidence: consultations, workforce, screening, student studies and rehabilitation capacity answer different questions about care and recovery.
Read →Clinical resource
Europe’s Prescription Divide: More Medication Is Not a Recovery League Table
Antidepressant consumption differs sharply across European countries. A comparison of OECD prescribing and patient-reported data explains why medication volume cannot rank recovery.
Read →Clinical resource
More Access Is Not the Same as Recovery: The Global Mental-Health Gap That Wealth Alone Cannot Measure
Global depression-treatment estimates, a 2026 quality-of-care study and WHO system indicators expose three different gaps: reaching care, receiving an appropriate pathway and measuring whether…
Read →Clinical resource
The Chatbot Beat a Waiting List. It Did Not Beat a Therapist.
The Therabot trial offers promising symptom findings, but not a head-to-head comparison with human therapy. For private and internationally mobile patients, availability, privacy and…
Read →